🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Leicester
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Leicester

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 99 Manchester 39 Cambridge 26 Glasgow 23 Bristol 17
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca17 Merck Sharp & Dohme LLC15 Hoffmann-La Roche14 Sanofi9 Boehringer Ingelheim8 Clear sponsor filter
Site city
London99 Manchester39 Cambridge26 Glasgow23 Bristol17
All 91 cities
Target enrolment
to
15 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
NCT07489495Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
758
Edinburgh, Leicester, Withington, Birmingham
2026-04-09
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558Ovarian Neoplasms, Ovarian Cancer
Merck Sharp & Dohme LLC
Phase 3
900
Cambridge, Leicester, London, Manchester
2026-02-16
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
675
Truro, London, Birmingham, Leicester
2025-10-08
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,000
London, Leicester, Manchester
2025-07-21
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
2,400
London, Dundee, Huddersfield, Colchester, Orpington, Nottingham, Blackpool, Leicester
2025-06-30
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
1,123
East Sussex, Cambridge, Glasgow, London, Edinburgh, Leicester, Maidstone, Manchester
2025-05-22
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Merck Sharp & Dohme LLC
Phase 3
770
Cambridge, Edinburgh, Preston, London, Sutton, Birmingham, Leicester, Liverpool
2025-04-09
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 3
680
Bristol, London, Nottingham, Leeds, Leicester, Manchester, Metropolitan Borough of Wirral, Portsmouth
2024-10-21
Active, closed
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
NCT05609968Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 3
614
Leicester, London, Metropolitan Borough of Wirral
2023-02-06
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
Merck Sharp & Dohme LLC
Phase 3
643
East Sussex, Cambridge, Truro, Kendal, Dundee, Leicester, London, Cardiff
2021-12-13
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
342
Truro, Leicester, London, Manchester, Blackpool, Londonderry
2021-06-18
Active, closed
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
990
Bristol, Cottingham, Glasgow, London, Sutton, Leicester, Manchester
2021-01-10
Active, closed
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
NCT04626518Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 1/2
370
Southampton, Glasgow, Preston, Leicester, London, Edinburgh, Cardiff, Manchester
2020-12-17
Active, closed
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
NCT04626479Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 1/2
400
Southampton, Glasgow, Preston, Leicester, London, Edinburgh, Cardiff, Manchester
2020-12-16
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
797
Leicester, Metropolitan Borough of Wirral, London, Sutton, Nottingham, Birmingham, Newcastle upon Tyne, Plymouth
2018-04-24
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/leicester

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.